You are here:

Roche

Name SMC ID No Status Sub. Type
 
alectinib hydrochloride (Alecensa) 1257/17 Not Recommended Non submission
bevacizumab (Avastin) 425/07 Not Recommended Non submission
bevacizumab (Avastin) 459/08 Superseded Non submission
bevacizumab (Avastin) 469/08 Superseded Full submission
bevacizumab (Avastin) 778/12 Not Recommended Full submission
bevacizumab (Avastin) 806/12 Not Recommended Full submission
bevacizumab (Avastin) 806/12 Not Recommended Resubmission
bevacizumab (Avastin) 806/12 Restricted Resubmission
bevacizumab (Avastin) 853/13 Not Recommended Full submission
bevacizumab (Avastin) 1135/16 Accepted Full submission
bevacizumab (Avastin) 1190/16 Not Recommended Non submission
bevacizumab (Avastin) 1063/15 Restricted Full submission
bevacizumab (Avastin) 1275/17 Not Recommended Non submission
Bevacizumab 100mg/4ml and 400mg/16ml solution for intravenous infusion (Avastin®) 221/05 Not Recommended Full submission
Bevacizumab 100mg/4ml and 400mg/16ml solution for intravenous infusion (Avastin®) 221/05 Not Recommended Resubmission
Bevacuzimab (Avastin) 387/07 Not Recommended Non submission
capecitabine (Xeloda) 507/08 Accepted Full submission
capecitabine (Xeloda) 716/11 Accepted Full submission
Capecitabine (Xeloda®) 34/03 Restricted Full submission
Capecitabine 150 and 500mg tablets (Xeloda®) 193/05 Accepted Full submission
capecitabine 150mg and 500mg tablets (Xeloda) 401/07 Accepted Full submission
cobimetinib (Cotellic) 1191/16 Not Recommended Non submission
Enfuvirtide (Fuzeon®) 56/03 Restricted Full submission
Erlotinib (Tarceva) 382/07 Not Recommended Non submission
erlotinib (Tarceva) 664/10 Not Recommended Full submission
erlotinib (Tarceva) 749/11 Accepted Full submission
Erlotinib (Tarceva®) 220/05 Superseded Resubmission
Erlotinib (Tarceva®) 220/05 Not Recommended Full submission
Ibandronic acid (Bondronat®) 123/04 Accepted Full submission
Ibandronic acid (Bondronat®) 122/04 Accepted Full submission
Ibandronic acid (Bonviva®) 228/05 Accepted Full submission
ibandronic acid, 3mg in 3ml solution for injection (Bonviva) 301/06 Restricted Full submission
Methoxy polyethylene glycol-epoetin beta 455/08 Accepted Full submission
obinutuzumab (Gazyvaro) 1008/14 Accepted Full submission
obinutuzumab (Gazyvaro) 1219/17 Accepted Full submission
obinutuzumab (Gazyvaro) 1286/18 Not Recommended Full submission
oseltamivir (Tamiflu) 1127/16 Accepted Abbreviated Submission
peginterferon alfa-2a (Pegasys) 561/09 Superseded Full submission
peginterferon alfa-2a (Pegasys) 1312/18 Not Recommended Non submission
Pegylated interferon alfa 2a (Pegasys®) 186/05 Accepted Full submission
pegylated interferon alfa-2a (Pegasys) 871/13 Superseded Abbreviated Submission
Pegylated interferon alfa-2a (Pegasys®) 10/02 Restricted Full submission
pertuzumab (Perjeta) 1121/16 Not Recommended Full submission
pertuzumab (Perjeta) 897/13 Not Recommended Full submission
pertuzumab (Perjeta) 897/13 Not Recommended Resubmission
pertuzumab (Perjeta) 897/13 Not Recommended Resubmission
pertuzumab (Perjeta) 1121/16 Not Recommended Resubmission
rituximab (MabThera) 493/08 Superseded Full submission
rituximab (MabThera) 540/09 Restricted Full submission
rituximab (MabThera) 591/09 Restricted Full submission
rituximab (Mabthera) 675/11 Restricted Full submission
rituximab (Mabthera) 894/13 Restricted Full submission
Rituximab (MabThera®) 135/04 Accepted Full submission
Rituximab (MabThera®) 33/03 Restricted Full submission
rituximab 100mg/10ml, 500mg/50ml ml solution for intravenous infusion (MabThera) 323/06 Superseded Full submission
rituximab 10mg/ml concentrate for infusion (MabThera) 330/06 Restricted Full submission
rituximab subcutaneous (Mabthera) 975/14 Restricted Full submission
tocilizumab (RoActemra) 593/09 Superseded Full submission
tocilizumab (RoActemra) 754/12 Accepted Full submission
tocilizumab (RoActemra) 774/12 Not Recommended Full submission
tocilizumab (RoActemra) 774/12 Superseded Resubmission
tocilizumab (RoActemra®) 1201/16 Not Recommended Non submission
tocilizumab (RoActemra®) 1020/14 Not Recommended Non submission
tocilizumab (RoActemra®) 982/14 Restricted Full submission
tocilizumab (RoActerma) 930/13 Superseded Abbreviated Submission
trastuzumab (Herceptin) 386/07 Superseded Non submission
trastuzumab (Herceptin) 623/10 Not Recommended Full submission
trastuzumab (Herceptin) 623/10 Not Recommended Resubmission
trastuzumab (Herceptin) 623/10 Restricted Resubmission
trastuzumab (Herceptin) 928/13 Restricted Full submission
Trastuzumab 150mg vial (Herceptin) 278/06 Restricted Full submission
trastuzumab emtansine (Kadcyla) 990/14 Not Recommended Full submission
trastuzumab emtansine (Kadcyla) 990/14 Accepted Resubmission
valganciclovir (Valcyle) 587/09 Restricted Abbreviated Submission
Valganciclovir (Valcyte) 21/02 Restricted Full submission
Valganciclovir (Valcyte) 62/03 Restricted Abbreviated Submission
valganciclovir (Valcyte) 586/09 Restricted Abbreviated Submission
valganciclovir (Valcyte) 662/10 Restricted Full submission
vemurafenib (Zelboraf) 792/12 Not Recommended Full submission
vemurafenib (Zelboraf) 792/12 Restricted Resubmission
vismodegib (Erivedge) 924/13 Not Recommended Non submission

Back